Anti-Neuroinflammatory Effects of Vanillin Through the Regulation of Inflammatory Factors and NF-κB Signaling in LPS-Stimulated Microglia.


Journal

Applied biochemistry and biotechnology
ISSN: 1559-0291
Titre abrégé: Appl Biochem Biotechnol
Pays: United States
ID NLM: 8208561

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 15 05 2018
accepted: 01 08 2018
pubmed: 12 8 2018
medline: 18 4 2019
entrez: 12 8 2018
Statut: ppublish

Résumé

Microglia, resident macrophages of the central nervous system (CNS), is responsible for immune responses and homeostasis of the CNS. Microglia plays a complex role in neuroinflammation, which has been implicated in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Therefore, therapeutic agents that suppress the microglia-mediated inflammatory response could potentially be used in the prevention or treatment of neurodegenerative diseases. Vanillin, a primary component of vanilla bean extract, has anti-inflammatory, anticancer, and antitumor properties. However, the effects of vanillin on the anti-neuroinflammatory responses of microglial cells are still poorly understood. In this study, we investigated the mechanism by which vanillin induces anti-neuroinflammatory responses in lipopolysaccharide (LPS)-stimulated BV-2 microglial cells. We found that vanillin significantly decreased the production of nitric oxide and pro-inflammatory cytokines, including interleukin (IL)-1β, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). Vanillin also reduced the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2), as well as the mRNA expression levels of IL-1β, TNF-α, and IL-6. Moreover, vanillin inhibited the phosphorylation of mitogen-activated protein kinases (MAPKs) and nuclear factor (NF)-κB. Collectively, these results suggest that vanillin has anti-neuroinflammatory properties and may act as a natural therapeutic agent for neuroinflammatory diseases.

Identifiants

pubmed: 30097802
doi: 10.1007/s12010-018-2857-5
pii: 10.1007/s12010-018-2857-5
doi:

Substances chimiques

Benzaldehydes 0
Inflammation Mediators 0
Lipopolysaccharides 0
NF-kappa B 0
Nitric Oxide 31C4KY9ESH
vanillin CHI530446X
Nitric Oxide Synthase Type II EC 1.14.13.39
Cyclooxygenase 2 EC 1.14.99.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

884-893

Subventions

Organisme : Marine Biotechnology Program
ID : PJT200669

Auteurs

Mi Eun Kim (ME)

Department of Life Science, Immunology Research Lab, BK21-plus Research Team for Bioactive Control Technology, College of Natural Sciences, Chosun University, Dong-gu, Gwangju, 501-759, Republic of Korea.

Ju Yong Na (JY)

Department of Life Science, Immunology Research Lab, BK21-plus Research Team for Bioactive Control Technology, College of Natural Sciences, Chosun University, Dong-gu, Gwangju, 501-759, Republic of Korea.

Yong-Duk Park (YD)

Djkunghee Hospital, Department of Preventive and Society Dentistry, School of Dentistry, Kyung Hee University, Seoul, 02447, South Korea. iam2875@khu.ac.kr.

Jun Sik Lee (JS)

Department of Life Science, Immunology Research Lab, BK21-plus Research Team for Bioactive Control Technology, College of Natural Sciences, Chosun University, Dong-gu, Gwangju, 501-759, Republic of Korea. junsiklee@chosun.ac.kr.

Articles similaires

C-Reactive Protein Humans Biomarkers Inflammation
Humans Immune Checkpoint Inhibitors Lung Neoplasms Prognosis Inflammation

The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma.

Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli et al.
1.00
Humans Multiple Myeloma Receptors, Fibroblast Growth Factor Fibroblast Growth Factors Proto-Oncogene Proteins c-myc
Animals Natural Killer T-Cells Mice Adipose Tissue Lipid Metabolism

Classifications MeSH